PPAR-Alpha Agonist Fenofibrate Combined with Octreotide Acetate in the Treatment of Acute Hyperlipidemia Pancreatitis
At present, there are more and more patients with acute hypertriglyceridemia pancreatitis in clinical practice. Common treatment measures include fasting and water withdrawal, fluid resuscitation, and somatostatin. In recent years, studies have pointed out that the PPARa agonist fenofibrate may help...
Saved in:
Main Authors: | Wen Bao, Rui Kong, Nan Wang, Wei Han, Jie Lu |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2021-01-01
|
Series: | PPAR Research |
Online Access: | http://dx.doi.org/10.1155/2021/6629455 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
PPAR-α Agonist Fenofibrate Decreased Serum Irisin Levels in Type 2 Diabetes Patients with Hypertriglyceridemia
by: Xiaomeng Feng, et al.
Published: (2015-01-01) -
Safety assessment of rosuvastatin-fenofibrate combination in the treatment of hyperlipidemia based on FDA’s adverse event reporting system database
by: Qun Li, et al.
Published: (2025-02-01) -
Fenofibrate Exerts Antitumor Effects in Colon Cancer via Regulation of DNMT1 and CDKN2A
by: Rui Kong, et al.
Published: (2021-01-01) -
Efficacy of double filtration plasmapheresis in hyperlipidemia acute pancreatitis: a retrospective observational study
by: Rong Qin, et al.
Published: (2025-01-01) -
Severe Hyperlipidemia Induced Hemorrhagic Pancreatitis during Pregnancy
by: Karen L. Koscica, et al.
Published: (2009-01-01)